##1. The Dilemma of Ultra‑Early Ischemic Stroke Treatment: Intravenous Thrombolysis and the Fear of Re‑occlusion Intravenous thrombolytics (e.g., tPA) are the standard of care for ultra‑early ischemic stroke, restoring patency to occluded cerebral vessels. However, immediately after clot dissolution, intense platelet‑mediated activation frequently leads to vessel re‑occlusion. Although there is a biological rationale for administering antiplatelet agents early to prevent this, clinicians have strictly contraindicated such use because of the fear that antiplatelet therapy within 24 hours of IV thrombolysis dramatically increases the risk of symptomatic intracranial hemorrhage (sICH).

##2. TAPIS Clinical Trial: A Phenotype‑Stratified Strategy Beyond the ‘One‑Size‑Fits‑All’ Approach The TAPIS trial, conducted by Professor Anxin Wang’s group and published in The Lancet, confronted this entrenched binary limitation by implementing patient stratification. To avoid the blanket risk of early antiplatelet therapy in all stroke patients, the investigators used advanced imaging and biomarkers to pre‑define a specific phenotype characterized by low hemorrhagic risk but extremely high platelet‑mediated re‑occlusion risk, and they initiated early antiplatelet therapy exclusively in this subgroup through an innovative protocol.

##3. Reduction of Recurrent Cerebral Injury Without Increased Bleeding: Clinical Validation of the Biological Mechanism The trial results were striking. In the precisely selected phenotype cohort, early antiplatelet co‑administration after thrombolysis did not lead to a statistically significant increase in hemorrhagic complications compared with controls. Conversely, the incidence of platelet‑driven microthrombi and recurrent ischemic injury was markedly reduced. These findings indicate that, when appropriate patient selection is applied, the longstanding conservative practice of withholding therapy out of hemorrhagic fear can be safely reversed.

##4. Comprehensive Revision of Stroke Guidelines Based on Precision Neurology The study is pivotal because it demonstrates the efficacy of ‘precision neurology’—treating stroke not as a monolithic disease but by tailoring therapeutic timing to individual genetic and phenotypic differences. The success of the TAPIS trial is expected to prompt a global revision of acute stroke guidelines, relaxing the 24‑hour prohibition on antiplatelet agents and incorporating phenotype screening into the standard of care. This will also profoundly influence the design of screening algorithms for future drug and combination‑therapy trials.